Nuchev Ltd (ASX: NUC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nuchev Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$21.22 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
146.34 million
Earnings per share
-0.116
Dividend per share
N/A
Year To Date Return
-28.95%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nuchev Ltd (ASX: NUC)
Latest News
Share Gainers
Why Iron Road, Nuchev, Telix, & Treasury Wine shares are pushing higher today
⏸️ Shares to Watch
Should you buy these 2 ASX dairy shares instead of A2 Milk?
Growth Shares
A2 Milk and 1 other top ASX growth share to buy this month
Share Market News
3 quarterly updates you might have missed: Champion Iron, Life360, & Nuchev
Share Market News
Why I'd buy and hold a2 Milk shares until 2025
Share Market News
Is the a2 Milk share price too high to buy?
Share Market News
Fund managers have been buying these ASX shares this week
Share Market News
This ASX infant formula share just reported explosive growth. Could it be the next a2 Milk?
Share Market News
2 ASX 200 companies playing a vital role in the coronavirus crisis
Share Market News
3 ASX shares to buy with $3,000
Share Market News
3 top ASX growth shares to diversify your portfolio
Share Market News
3 ASX growth shares to buy and hold beyond 2025
1❯
NUC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nuchev Ltd
Nuchev Ltd is a globally-oriented food business focused on developing, marketing, and selling a range of premium Australian made goat nutritional products. Its primary products include those branded under the Oli6 Bio Practica and MedicineTree and a number of globally recognized European brands sold under exclusive license in Australia and New Zealand by bWellness.
NUC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Oct 2024 | $0.15 | $-0.01 | -6.67% | 609 | $0.15 | $0.15 | $0.15 |
| 04 Oct 2024 | $0.15 | $0.00 | 0.00% | 153,644 | $0.15 | $0.15 | $0.15 |
| 01 Oct 2024 | $0.15 | $0.01 | 6.90% | 325 | $0.15 | $0.15 | $0.15 |
| 30 Sep 2024 | $0.15 | $-0.01 | -6.67% | 7,253 | $0.15 | $0.15 | $0.15 |
| 27 Sep 2024 | $0.15 | $0.00 | 0.00% | 2,180 | $0.15 | $0.15 | $0.15 |
| 24 Sep 2024 | $0.15 | $0.00 | 0.00% | 250 | $0.15 | $0.15 | $0.15 |
| 20 Sep 2024 | $0.15 | $-0.01 | -6.45% | 20,000 | $0.15 | $0.15 | $0.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 29 Jul 2024 | Ben Dingle | Expiry | 1,646,090 | $296,296 |
Options expired.
|
| 27 Jun 2024 | Craig Silbery | Issued | 2,271,561 | $354,363 |
Rights issue.
|
| 27 Jun 2024 | Craig Silbery | Issued | 1,342,766 | $209,471 |
Rights issue.
|
| 27 Jun 2024 | Ben Dingle | Issued | 5,769,231 | $900,000 |
Rights issue.
|
| 16 Oct 2023 | Ben Dingle | Transfer | 11,976,000 | $2,095,800 |
Off-market transfer.
|
| 16 Oct 2023 | Ben Dingle | Transfer | 11,976,000 | $2,095,800 |
Off-market transfer.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ben McFarlane Dingle | Executive DirectorExecutive Chairman | Apr 2013 |
Ben is recognised as a highly connected, large scale dairy innovator and leader. He has extensive commercial experience in the wider dairy nutritional sector. Ben was also instrumental in the creation and management of a portfolio encompassing expansive dairy operations on the Canterbury Plains, which included approximately 15,000 cows. In this role, he established and implemented innovative irrigation schemes, and the incorporation of world best farming practices. Ben was a member and Chair of the Group's Strategy and M&A Committee.
|
| Ms Elizabeth Smith (Liz) | Non-Executive Director | Jul 2024 |
Ms Smith has executive career includes Corporate Finance Partner roles at William Buck and Grant Thornton, as well as audit experience at Ernst & Young. L Smith is on the Board of the Australian Red Cross Pureprofile (ASX:PPL) and BikeExchange (formerly ASX: BEX). L Smith has skills in finance and accounting, strategy, M&A, risk and governance and experience advising businesses. She has worked across a range of industries (including food and fast-moving consumer goods) and for businesses ranging from small privately owned companies to large ASX listed entities.
|
| Mr Craig Silbery | Non-Executive Director | Oct 2023 |
Mr Silbery is a entrepreneur who established and led Life-Space Group from start-up to a exit with the sale to Guangzhou based By-Health in 2018. He built Life-Space around a core foundation of innovatve probiotic formulas for infants and pregnant women developed based on Human Microbiome science. He is also currently the founder and CEO of ilume, a wearable pet health venture
|
| Mr Nathan Alexander Xavier Cheong | Non-Executive Director | Sep 2024 |
Mr Cheong brings over 20 years of experience within the medicine industry. Nathan Cheong is a Director, Managing Director and CEO. His executive career includes CEO roles at Melrose Group and LifeSpace Group, Managing Director roles at Designs for Health, Blackmores owned BioCeuticals practitioner only brand, Global Therapeutics, and as General Manager and Director at Herbs of Gold (formerly ASX:VSC). Nathan has also served as a Non-Executive Director on the Board of Complementary Medicines Australia.
|
| Ms Tamara Barr | Company Secretary | Feb 2022 |
-
|
| Mr Michael(Mick) Loe Myers | Chief Executive Officer | Dec 2023 |
-
|
| Michael(Mick) Loe Myers | Chief Executive Officer |
-
|
|
| Tamara Barr | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Ben Dingle | 32,084,449 | 38.01% |
| H&S Investments Australia Pty Ltd <H&S Investment Unit A/C> | 16,797,049 | 19.90% |
| HSBC Custody Nominees (Australia) Limited | 12,793,825 | 15.16% |
| Mr Craig Silbery | 3,692,604 | 4.37% |
| CW Investment Holdings A/C <CW Investment Holdings A/C> | 1,030,000 | 1.22% |
| Kirwood Capital Direct Investments 1 Pty Ltd <Kirwood Cap Direct Invest 1> | 1,000,000 | 1.18% |
| Superhero Securities Limited <Client A/C> | 953,900 | 1.13% |
| Justin Breheny | 937,008 | 1.11% |
| Gigo Investment Pty Ltd <Gigo A/C> | 874,949 | 1.04% |
| Ataturk Investments Pty Ltd | 565,067 | 0.67% |
| Top End Enterprises Pty Ltd <Atkins Super Fund A/C> | 405,771 | 0.48% |
| Daho Pty Ltd <The DHB S/F A/C> | 350,000 | 0.41% |
| Pacific Healthy International Holding Pty Ltd | 317,097 | 0.38% |
| Mr Pynith Charernsirivathin & Mrs Zina Christina Charernsirivathin | 300,000 | 0.36% |
| MF & SA Super Pty Ltd <MF & SA Super A/C> | 277,000 | 0.33% |
| Sharma Investments Pty Ltd <Sharma Invest Disc A/C> | 245,771 | 0.29% |
| Mango & Chubb Pty Ltd <Superannuation Fund A/C> | 240,000 | 0.28% |
| Mr Lawrence Wing Ming Ho & Mrs Ying Ho <L&Y Family Super Fund A/C> | 235,919 | 0.28% |
| MGD Strategic Acquisitions P/L <MGD Strat Acquisitions A/C> | 228,545 | 0.27% |
| Thomas Edward Dingle & Patricia Jessie Dingle <Clyde Hill A/C> | 225,000 | 0.27% |
